Literature DB >> 25189728

Does anything work for anaemia in myelofibrosis?

Gunnar Birgegård1.   

Abstract

Anaemia is a common finding at diagnosis in myelofibrosis, and becomes a symptomatic problem in most patients with time. There are several treatment options for specific anaemia treatment, none of which has been tested in large, randomized, controlled trials. However, as myelofibrosis is not a disease with spontaneous remissions, even non-randomized trials carry weight. In this survey, the existing evidence will be analysed, both for the commonly used treatments like erythropoiesis-stimulating agents, androgens and thalidomide and for the new drugs in the area, and conclusions will be drawn concerning standard clinical anaemia treatment in myelofibrosis, which according to evidence from studies has a 40-50% chance of response in patients with not too advanced disease.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  anaemia; anaemia treatment; myelofibrosis; myeloproliferative neoplasm

Mesh:

Substances:

Year:  2014        PMID: 25189728     DOI: 10.1016/j.beha.2014.07.011

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  7 in total

Review 1.  Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Tiziano Barbui; Omar Abdel-Wahab; Robert Kralovics; Catriona Jamieson; Hans-Michael Kvasnicka; Ann Mullaly; Raajit Rampal; Ruben Mesa; Jean-Jacques Kiladjian; Michael Deininger; Josef Prchal; Rüdiger Hehlmann; Giuseppe Saglio; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-11-19

Review 2.  JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Blood       Date:  2017-05-12       Impact factor: 22.113

Review 3.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

Review 4.  Myelofibrosis: an update on drug therapy in 2016.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Expert Opin Pharmacother       Date:  2016-11-07       Impact factor: 3.889

Review 5.  Developmental Therapeutics in Myeloproliferative Neoplasms.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-07

Review 6.  Profile of pomalidomide and its potential in the treatment of myelofibrosis.

Authors:  Krisstina L Gowin; Ruben A Mesa
Journal:  Ther Clin Risk Manag       Date:  2015-04-02       Impact factor: 2.423

7.  Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies.

Authors:  Leonard Naymagon; John Mascarenhas
Journal:  Hemasphere       Date:  2017-12-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.